HOOKIPA Pharma Inc. (HOOK): Price and Financial Metrics


HOOKIPA Pharma Inc. (HOOK): $6.76

0.21 (+3.21%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

HOOK Stock Price Chart Interactive Chart >

Price chart for HOOK

HOOK Price/Volume Stats

Current price $6.76 52-week high $20.00
Prev. close $6.55 52-week low $6.01
Day low $6.38 Volume 147,300
Day high $6.82 Avg. volume 290,915
50-day MA $7.15 Dividend yield N/A
200-day MA $11.11 Market Cap 176.25M

HOOKIPA Pharma Inc. (HOOK) Company Bio


HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body's immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.


HOOK Latest News Stream


Event/Time News Detail
Loading, please wait...

HOOK Latest Social Stream


Loading social stream, please wait...

View Full HOOK Social Stream

Latest HOOK News From Around the Web

Below are the latest news stories about HOOKIPA Pharma Inc that investors may wish to consider to help them evaluate HOOK as an investment opportunity.

HOOKIPA nears five-month low as SVB Leerink expects near-term pressure

Photo by tolgart/iStock via Getty Images Having lost more than a fifth of its value yesterday, HOOKIPA Pharma ([[HOOK]] -16.8%) is continuing the slide in reaction to the company’s updated data from the Phase 1/2 study for HB-200 in the treatment of advanced Human Papillomavirus 16-positive (HPV16+) cancers. The company evaluated...

Seeking Alpha | June 8, 2021

HOOKIPA Pharma slumps on Phase 1/2 data for lead cancer therapies

HOOKIPA Pharma ([[HOOK]] -7.1%) has sharply today after announcing an abstract that includes data for its lead assets HB-201 and HB-202 in advanced Human Papillomavirus 16-positive (HPV16+) cancers.The abstract will be part of an oral presentation scheduled for June 07 at the upcoming 2021 American Society of Clinical Oncology ((ASCO)) Annual Meeting.The...

Seeking Alpha | May 20, 2021

Read More 'HOOK' Stories Here

HOOK Price Returns

1-mo 0.45%
3-mo -27.93%
6-mo -51.23%
1-year -29.07%
3-year N/A
5-year N/A
YTD -39.04%
2020 -9.32%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8256 seconds.